Get Hyped for Scalable 3D Cell Culture Technology
Meet InSphero at SLAS2022, the annual meeting of the Society of Laboratory Automation & Screening, in Boston, February 5-9. We are hyped to be back in person this year and are looking forward to reconnecting with the life sciences and technology community. SLAS2022 will feature inspiring keynotes and plenary speakers, networking opportunities, and a fully interactive exhibition featuring innovative product and service demonstrations and tutorials.
- An exclusive first look at our NEW Akura™ Spheroid Microplate, which will be available for purchase at shop.insphero.com
- Our full Akura™ technology portfolio, engineered specifically for use with 3D InSight™ Human Microtissue models, as well as our unrivaled, plug-and-play 80-well microphysiological organ-on-a-chip system
- Live demonstrations of the superior imaging quality of Akura™ 384-well plate, together with our partners from Yokogawa at booth #424
- Versatile research platforms for metabolic diseases (type 2 diabetes and NASH), autoimmune diseases (type 1 diabetes) oncology, and liver toxicology
- 3D InSight™ Microtissue Models precisely engineered to increase efficiency in drug discovery and safety testing, available as assay-ready spheroid models or as the foundation for custom services or collaborative research programs
Development of a 3D-optimized microplate enables confocal high content imaging with cell level resolution and the automation of immuno-staining methods for spheroid models
Closing the gap between 3D model development and high-through put implementation
Monday, February 7
1:30 – 2:00 PM EST / Room: 210B
Presenter: Ms. Judi Wardwell – Swanson, Senior Scientist, Technology & Platforms, InSphero
Tuesday, February 8
12:30 – 12:50 PM EST / Room: Exhibition Theater #2644
Presenter: Dr. Olivier Frey, Vice-president Technology & Platforms, InSphero
As the dependence on 3D models and high content imaging continues to expand, maximizing 3D image quality is imperative to the development of accurate and comprehensive spheroid measurements. Likewise, the implementation of reliable automated workflows is essential to the adoption of 3D models for screening applications. During the live talk, Ms. Judi Wardwell will explore two promising innovations, spheroid microtissues, and 3D microplates, which may soon overcome the remaining obstacles limiting the broader utilization 3D cell models in early drug discovery.
InSphero’s success in engineering physiological-relevant, yet pragmatic 3D spheroid solutions is grounded on a unique pairing of plate technologies with 3D tissue development expertise. Join Dr. Frey to learn about the entry points we offer to these technology platforms differing in complexity and effort required for routine implementation. You will find about our commercially available “empty” microplate formats, as well as the quality-controlled assay-ready microtissues delivered directly to your lab on demand. And lastly, we will share details about an upcoming product launch that will help you generate your own perfect 3D microtissues right out of the gate.
3D Cell-Based Assays and Organ-on-Chip Systems for Drug Discovery and Safety
Sunday, February 6
8:30 AM – 4:30 PM / Room: 102B
Presenters: Dr. Terry Riss, Promega, Dr. Marc Ferrer, NIH, Dr. Olivier Frey, InSphero, Prof. Paul A. Johnston, University of Pittsburgh, Madhu Lal-Nag, FDA, Dr. Jan Lichtenberg, InSphero
We are honored to join this short course session and discuss the latest advances in 3D cell culture technologies, assays and their use in drug discovery and development. Organ-on-chip devices and 3D bioprinting round off the curriculum. During the educational course, the speakers will cover:
- In-depth overview of 3D cell culture technologies and models: Comparison of the most important methods for 3D cell culture including scaffold-free, hydrogel, bioprinting and multi-organ devices; implementation strategies, automation, and work flows; comparison of advantages, disadvantages and cost.
- How to choose and adapt fit-for-purpose assays and readouts for 3D cell culture models: Using and optimizing existing biochemical assays; applying imaging technology and high-content analysis for more biological insights; histology and immune histochemistry; use of machine-learning techniques to quantify imaging data
- Case studies for the use of 3D models in drug discovery: 3D tumor models; co-culture systems; applications in screening of large libraries; target validation, 3D-based phenotypic drug discovery
- Case studies for the use of multi-organ-on-chip systems: Systemic microfluidic interaction of organ models derived either from primary cell sources or stem cells and their use for disease modelling, such as the metabolic syndrome, as well as safety testing including inflammation-mediated toxicology.